CN106619686A - Western medicine for treating bronchiectasis - Google Patents
Western medicine for treating bronchiectasis Download PDFInfo
- Publication number
- CN106619686A CN106619686A CN201611171838.2A CN201611171838A CN106619686A CN 106619686 A CN106619686 A CN 106619686A CN 201611171838 A CN201611171838 A CN 201611171838A CN 106619686 A CN106619686 A CN 106619686A
- Authority
- CN
- China
- Prior art keywords
- parts
- western medicine
- triptophenolide
- beta
- bronchiectasis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
The invention discloses a western medicine for treating bronchiectasis. The western medicine for treating the bronchiectasis is prepared from the following main raw materials in parts by weight: 5 to 11 parts of beta,beta-dimethylacrylshikonin, 23 to 28 parts of ethoxychelerythrine, 6 to 15 parts of eupalinolide A, 5 to 12 parts of emetini hydrochloridium, 17 to 26 parts of triptophenolide, 8 to 12 parts of triptophenolide, 2 to 4 parts of dalbergin, 3 to 6 parts of 7,8-dihydroxyl-4-phenylcoumarin and 7 to 8 parts of XinBeijiaprime-3beta-D-glucoside. According to the medicine disclosed by the invention, raw material components are strictly selected according to a know mechanism of the bronchiectasis, so that the aim of comprehensive rehabilitation is realized; the western medicine has the characteristics of rapid effect, stability in acting, convenience for taking and orally administering and has no toxic or side effect after the western medicine is orally administered for a long period.
Description
Technical field
The present invention relates to a kind of field of medicine preparation, specifically a kind of Western medicine for treating bronchiectasis.
Background technology
Bronchiectasis is, due to bronchus and its surrounding lung tissue chronic suppurative inflammation and fibrillatable, to make bronchial wall
Muscle and elastic fibrous tissue destruction, cause bronchus to deform and persistently expansion.Main pathogenic be bronchial infection, obstruction and
Drawing, partly there is congenital heredity factor.Being in chronic process the bronchiectasis course of disease, typical clinical manifestations are chronic cough, cough more
A large amount of phlegms and spit blood repeatedly.90% patient often has spitting of blood, varying degree.Some patients, spitting of blood is probably that its is starting and only
Main suit, be clinically referred to as " dry bronchiectasis ", be common in tuberculous bronchiectasis, pathology is more in superior lobar branch tracheae.
If scabies secondary infection repeatedly, there are heating, night sweat during patient, weak, anorexia, become thin.When the concurrent compensatory of bronchiectasis
Or during obstructive emphysema, patient can have expiratory dyspnea, an out of breath or cyanosis, late period may occur in which pulmonary heart disease and cardiorespiratory failure
Performance.
This sick any age all can fall ill, but common with teenager, and many childhood are with pneumonia after measles, pertussis or influenza
Medical history, or have the medical histories such as pulmonary tuberculosis, endobraonchial tuberculosis, pulmonary fibrosis.This sick Later development has multiple complications, may lead
Cause lung collapse.
The bronchiectasis cause of disease includes infection, heredity, cilium exception, immune deficiency, foreign-body aspiration etc., and pathogenesis is
The infection and bronchial obstruction infection of Bronchi-pulmonary tissue cause hyperemia, the oedema of tube chamber mucous membrane, make the narrow and small secretion of tube chamber easy
Obstruction tube chamber, causes inadequate drainage and increases infection；Bronchial obstruction inadequate drainage can induce pulmonary infection.Current western medicine
There are ampicillin, Amoxicillin or a carbostyril antibiotic, or erythromycin, ROX, CLA and azithromycin etc. are anti-
Scorching medicine, but its therapeutic effect is undesirable and side effect is larger.But at present Chinese medicine there is also that treatment course is longer, DeGrain
The problems such as.
The content of the invention
It is an object of the invention to provide a kind of Western medicine for treating bronchiectasis, to solve above-mentioned background technology in carry
The problem for going out.
For achieving the above object, the present invention provides following technical scheme：
A kind of Western medicine for treating bronchiectasis, be according to the primary raw material of weight portion：Beta, beta-dimethyl acryloyl is purple
Careless element 5-11 parts, ethoxychelerythrine 23-28 parts, Eupalinolide A 6-15 parts, emetine hydrochloride 5-12 parts, in thunder phenol
Ester 17-26 parts, triptophenolide 8-12 parts, dalbergin 2-4 parts, 7,8- dihydroxy -4- phenyl coumarin 3-6 parts, pungent shellfish A prime -3
β-D-Glucose glycosides 7-8 parts.
As further scheme of the invention：The Western medicine of the treatment bronchiectasis, according to the main original of weight portion
Expect be：Beta, beta-dimethyl acryloyl alkannin 6-9 parts, ethoxychelerythrine 25-26 parts, Eupalinolide A 6-15 parts,
Emetine hydrochloride 6-10 parts, triptophenolide 19-22 parts, triptophenolide 9-11 parts, dalbergin 2-4 parts, 7,8- dihydroxy -4- phenyl
Cumarin 3-6 parts, -3 β of pungent shellfish A prime-D-Glucose glycosides 7-8 parts.
As further scheme of the invention：The Western medicine of the treatment bronchiectasis, according to the main original of weight portion
Expect be：8 parts of beta, beta-dimethyl acryloyl alkannin, 26 parts of ethoxychelerythrine, 12 parts of Eupalinolide A, hydrochloric acid ipecac
8 parts of alkali, 21 parts of triptophenolide, 10 parts of triptophenolide, 3 parts of dalbergin, 5 parts of 7,8- dihydroxy -4- phenyl coumarins, Xin Beijia
- 3 β of element -8 parts of D-Glucose glycosides.
A kind of preparation method of the Western medicine for treating bronchiectasis, concretely comprises the following steps：
First, in pharmaceutical grade clean area, β is weighed by above-mentioned metering ratio, beta-dimethyl acryloyl alkannin, ethyoxyl are white
The red alkali of dish in the wrong, Eupalinolide A, emetine hydrochloride, triptophenolide, triptophenolide, dalbergin, 7,8- dihydroxy -4- phenyl are fragrant
Legumin, -3 β of pungent shellfish A prime-D-Glucose glycosides, sieve, and machinery adds ultra-pure water after mixing, and in placing pharmacy mixer, mix 4-
8min, controls RSD≤5%, compressing tablet and low temperature drying after mixing, and at 4-8 DEG C, packaging obtains final product treatment bronchiectasis to temperature control
The Western medicine of disease.
As further scheme of the invention：Mix 6min in concrete steps.
Compared with prior art, the invention has the beneficial effects as follows：
Medicine of the present invention is strictly selected material composition according to the understanding mechanism of bronchiectasis, complete so as to reach
The purpose of face rehabilitation, with rapid-action, effect it is stable, carry taking convenience, long-term taking and have no toxic side effect the characteristics of.
Specific embodiment
Below in conjunction with the embodiment of the present invention, the technical scheme in the embodiment of the present invention is clearly and completely described,
Obviously, described embodiment is only a part of embodiment of the invention, rather than the embodiment of whole.Based in the present invention
Embodiment, the every other embodiment that those of ordinary skill in the art are obtained under the premise of creative work is not made, all
Belong to the scope of protection of the invention.
Embodiment 1
A kind of Western medicine for treating bronchiectasis, be according to the primary raw material of weight portion：Beta, beta-dimethyl acryloyl is purple
Careless 5 parts of element, 23 parts of ethoxychelerythrine, 6 parts of Eupalinolide A, 5 parts of emetine hydrochloride, 17 parts of triptophenolide, thunder phenol
8 parts of lactone, 2 parts of dalbergin, 3 parts of 7,8- dihydroxy -4- phenyl coumarins, -3 β of pungent shellfish A prime -7 parts of D-Glucose glycosides.
A kind of preparation method of the Western medicine for treating bronchiectasis, concretely comprises the following steps：
First, in pharmaceutical grade clean area, β is weighed by above-mentioned metering ratio, beta-dimethyl acryloyl alkannin, ethyoxyl are white
The red alkali of dish in the wrong, Eupalinolide A, emetine hydrochloride, triptophenolide, triptophenolide, dalbergin, 7,8- dihydroxy -4- phenyl are fragrant
Legumin, -3 β of pungent shellfish A prime-D-Glucose glycosides, sieve, and machinery adds ultra-pure water after mixing, in placing pharmacy mixer, mixing
4min, controls RSD≤5%, compressing tablet and low temperature drying after mixing, and at 4 DEG C, packaging obtains final product treatment bronchiectasis to temperature control
Western medicine.
Embodiment 2
A kind of Western medicine for treating bronchiectasis, be according to the primary raw material of weight portion：Beta, beta-dimethyl acryloyl is purple
Careless 6 parts of element, 25 parts of ethoxychelerythrine, 6 parts of Eupalinolide A, 6 parts of emetine hydrochloride, 19 parts of triptophenolide, thunder phenol
9 parts of lactone, 2 parts of dalbergin, 3 parts of 7,8- dihydroxy -4- phenyl coumarins, -3 β of pungent shellfish A prime -7 parts of D-Glucose glycosides.
A kind of preparation method of the Western medicine for treating bronchiectasis, concretely comprises the following steps：
First, in pharmaceutical grade clean area, β is weighed by above-mentioned metering ratio, beta-dimethyl acryloyl alkannin, ethyoxyl are white
The red alkali of dish in the wrong, Eupalinolide A, emetine hydrochloride, triptophenolide, triptophenolide, dalbergin, 7,8- dihydroxy -4- phenyl are fragrant
Legumin, -3 β of pungent shellfish A prime-D-Glucose glycosides, sieve, and machinery adds ultra-pure water after mixing, in placing pharmacy mixer, mixing
4min, controls RSD≤5%, compressing tablet and low temperature drying after mixing, and at 4 DEG C, packaging obtains final product treatment bronchiectasis to temperature control
Western medicine.
Embodiment 3
A kind of Western medicine for treating bronchiectasis, be according to the primary raw material of weight portion：Beta, beta-dimethyl acryloyl is purple
Careless 8 parts of element, 26 parts of ethoxychelerythrine, 12 parts of Eupalinolide A, 8 parts of emetine hydrochloride, 21 parts of triptophenolide, thunder phenol
10 parts of lactone, 3 parts of dalbergin, 5 parts of 7,8- dihydroxy -4- phenyl coumarins, -3 β of pungent shellfish A prime -8 parts of D-Glucose glycosides.
A kind of preparation method of the Western medicine for treating bronchiectasis, concretely comprises the following steps：
First, in pharmaceutical grade clean area, β is weighed by above-mentioned metering ratio, beta-dimethyl acryloyl alkannin, ethyoxyl are white
The red alkali of dish in the wrong, Eupalinolide A, emetine hydrochloride, triptophenolide, triptophenolide, dalbergin, 7,8- dihydroxy -4- phenyl are fragrant
Legumin, -3 β of pungent shellfish A prime-D-Glucose glycosides, sieve, and machinery adds ultra-pure water after mixing, in placing pharmacy mixer, mixing
6min, controls RSD≤5%, compressing tablet and low temperature drying after mixing, and at 6 DEG C, packaging obtains final product treatment bronchiectasis to temperature control
Western medicine.
Embodiment 4
A kind of Western medicine for treating bronchiectasis, be according to the primary raw material of weight portion：Beta, beta-dimethyl acryloyl is purple
Careless 9 parts of element, 26 parts of ethoxychelerythrine, 15 parts of Eupalinolide A, 10 parts of emetine hydrochloride, 22 parts of triptophenolide, thunder
11 parts of phenol lactone, 4 parts of dalbergin, 6 parts of 7,8- dihydroxy -4- phenyl coumarins, -3 β of pungent shellfish A prime -8 parts of D-Glucose glycosides.
A kind of preparation method of the Western medicine for treating bronchiectasis, concretely comprises the following steps：
First, in pharmaceutical grade clean area, β is weighed by above-mentioned metering ratio, beta-dimethyl acryloyl alkannin, ethyoxyl are white
The red alkali of dish in the wrong, Eupalinolide A, emetine hydrochloride, triptophenolide, triptophenolide, dalbergin, 7,8- dihydroxy -4- phenyl are fragrant
Legumin, -3 β of pungent shellfish A prime-D-Glucose glycosides, sieve, and machinery adds ultra-pure water after mixing, in placing pharmacy mixer, mixing
8min, controls RSD≤5%, compressing tablet and low temperature drying after mixing, and at 8 DEG C, packaging obtains final product treatment bronchiectasis to temperature control
Western medicine.
Embodiment 5
A kind of Western medicine for treating bronchiectasis, be according to the primary raw material of weight portion：Beta, beta-dimethyl acryloyl is purple
Careless 11 parts of element, 28 parts of ethoxychelerythrine, 15 parts of Eupalinolide A, 12 parts of emetine hydrochloride, 26 parts of triptophenolide, thunder
12 parts of phenol lactone, 4 parts of dalbergin, 6 parts of 7,8- dihydroxy -4- phenyl coumarins, -3 β of pungent shellfish A prime -8 parts of D-Glucose glycosides.
A kind of preparation method of the Western medicine for treating bronchiectasis, concretely comprises the following steps：
First, in pharmaceutical grade clean area, β is weighed by above-mentioned metering ratio, beta-dimethyl acryloyl alkannin, ethyoxyl are white
The red alkali of dish in the wrong, Eupalinolide A, emetine hydrochloride, triptophenolide, triptophenolide, dalbergin, 7,8- dihydroxy -4- phenyl are fragrant
Legumin, -3 β of pungent shellfish A prime-D-Glucose glycosides, sieve, and machinery adds ultra-pure water after mixing, in placing pharmacy mixer, mixing
8min, controls RSD≤5%, compressing tablet and low temperature drying after mixing, and at 8 DEG C, packaging obtains final product treatment bronchiectasis to temperature control
Western medicine.
Pharmacology test
1st, chronic toxicity test
With Western medicine obtained in the embodiment of the present invention 3 as test, using gastric infusion mode, successive administration 2 times in 24h,
Per minor tick 8h, 200mg/kg doses are administered every time, daily accumulation medicine total amount reaches 400mg medicines/kg, it is clinical equivalent to people to use
100 times of amount.After administration in 7d, mouse activity, feed, excretion are normal, well-grown, and hair color light, its average weight is equal
Increase with the prolongation of experimental period.Every mouse of post mortem at 8d, visually observe the heart, liver, spleen, lung, kidney, brain, thymus gland,
Stomach, intestines etc. do not find color and paramophia, fail to measure median lethal dose (LD50).As a result show：Western medicine of the present invention without
Chronic toxicity.
2nd, long term toxicity test
With Western medicine obtained in the embodiment of the present invention 3 as test, using gastric infusion mode, Western medicine of the present invention is divided into low dose
Amount, middle dosage, three groups of high dose, the drug dose of each group is respectively 40,80,120mg medicines/kg/d, equivalent to clinical dosage
10,20,30 times.After gastric infusion 24 weeks, medicine of the present invention refers to the general status of animal, hematological indices, blood biochemical
Mark without significantly impact, Systematic anatomy, organ coefficient and histopathological examination also no abnormal pathological change.Drug withdrawal 2
Also substantially change is had no week.As a result show：Western medicine of the present invention does not find that overt toxicity reacts and postpones in long term toxicity test
Toxic reaction.It can be seen that, Western medicine non-toxic reaction of the present invention, long-term prescription is safe and reliable.
3rd, clinical testing
In October, 2015, in Beijing, 165 patients screened in hospital in April, 2016, and all patients meet bronchus
Di diagnostic criteria is (according to the 7th edition《Clinical practice》The diagnostic criteria of bronchiectasis：According to pyoptysis phlegm repeatedly, spitting of blood
Medical history induces this sick respiratory tract infection medical history with previously having, and CT or HRCT shows bronchiectasic abnormal image performance,
This disease can be made a definite diagnosis).The wherein male sex 95, women 70, minimal ages 22 years old, max age 63 years old, average age 35.2 years old.
All patients take the Western medicine of the preparation of the embodiment of the present invention 3, and instructions of taking is：Daily 4mg/kg, 3 days courses for the treatment of, treat altogether
Three courses for the treatment of.
Curative effect situation criterion：Cure：Clinical symptoms are wholly absent, and chest CT check is normal；It is effective：Clinical symptoms base
This disappearance, chest CT check is clearly better；Effectively：Clinical symptoms improve, and chest CT check has taken a turn for the better；It is invalid：Clinical symptoms
Improve not substantially, before chest CT check is with treatment.
Therapeutic effect：165 patients have no adverse reaction during treating, healing 121, effective 22, effective 16, nothing
Effect 6, total effective rate 96.4%.
It is obvious to a person skilled in the art that the invention is not restricted to the details of above-mentioned one exemplary embodiment, Er Qie
In the case of spirit or essential attributes without departing substantially from the present invention, the present invention can be in other specific forms realized.Therefore, no matter
From the point of view of which point, embodiment all should be regarded as exemplary, and be nonrestrictive, the scope of the present invention is by appended power
Profit is required rather than described above is limited, it is intended that all in the implication and scope of the equivalency of claim by falling
Change is included in the present invention.
Moreover, it will be appreciated that although this specification is been described by according to embodiment, not each embodiment is only wrapped
Containing an independent technical scheme, this narrating mode of specification is only that for clarity those skilled in the art should
Using specification as an entirety, the technical scheme in each embodiment can also Jing it is appropriately combined, form those skilled in the art
Understandable other embodiment.
Claims (5)
1. a kind of Western medicine for treating bronchiectasis, it is characterised in that the primary raw material according to weight portion is：Beta, beta-dimethyl
Acryloyl alkannin 5-11 parts, ethoxychelerythrine 23-28 parts, Eupalinolide A 6-15 parts, emetine hydrochloride 5-12
It is part, triptophenolide 17-26 parts, triptophenolide 8-12 parts, dalbergin 2-4 parts, 7,8- dihydroxy -4- phenyl coumarin 3-6 parts, pungent
Shellfish -3 β of A prime-D-Glucose glycosides 7-8 parts.
2. it is according to claim 1 treatment bronchiectasis Western medicine, it is characterised in that the treatment bronchiectasis
The Western medicine of disease, be according to the primary raw material of weight portion：Beta, beta-dimethyl acryloyl alkannin 6-9 parts, ethoxychelerythrine
25-26 parts, Eupalinolide A 6-15 parts, emetine hydrochloride 6-10 parts, triptophenolide 19-22 parts, triptophenolide 9-11 parts, Huang
Wingceltis element 2-4 parts, 7,8- dihydroxy -4- phenyl coumarin 3-6 parts, -3 β of pungent shellfish A prime-D-Glucose glycosides 7-8 parts.
3. it is according to claim 1 and 2 treatment bronchiectasis Western medicine, it is characterised in that the treatment bronchus
The Western medicine of di, be according to the primary raw material of weight portion：8 parts of beta, beta-dimethyl acryloyl alkannin, ethyoxyl chelerythrine
26 parts of alkali, 12 parts of Eupalinolide A, 8 parts of emetine hydrochloride, 21 parts of triptophenolide, 10 parts of triptophenolide, 3 parts of dalbergin, 7,
5 parts of 8- dihydroxy -4- phenyl coumarins, -3 β of pungent shellfish A prime -8 parts of D-Glucose glycosides.
4. a kind of preparation method of the Western medicine of the treatment bronchiectasis as described in claim 1-3 is arbitrary, it is characterised in that
Concretely comprise the following steps：
First, in pharmaceutical grade clean area, β, beta-dimethyl acryloyl alkannin, ethyoxyl greater celandine are weighed by above-mentioned metering ratio
Red alkali, Eupalinolide A, emetine hydrochloride, triptophenolide, triptophenolide, dalbergin, 7,8- dihydroxy -4- phenyl coumarins,
- 3 β of pungent shellfish A prime-D-Glucose glycosides, sieve, and machinery adds ultra-pure water after mixing, and in placing pharmacy mixer, mix 4-8min,
Control RSD≤5%, compressing tablet and low temperature drying after mixing, at 4-8 DEG C, packaging obtains final product treatment bronchiectasis to temperature control
Western medicine.
5. it is according to claim 4 treatment bronchiectasis Western medicine preparation method, it is characterised in that concrete steps
Middle mixing 6min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611171838.2A CN106619686A (en) | 2016-12-17 | 2016-12-17 | Western medicine for treating bronchiectasis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611171838.2A CN106619686A (en) | 2016-12-17 | 2016-12-17 | Western medicine for treating bronchiectasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106619686A true CN106619686A (en) | 2017-05-10 |
Family
ID=58823964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611171838.2A Withdrawn CN106619686A (en) | 2016-12-17 | 2016-12-17 | Western medicine for treating bronchiectasis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106619686A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103063792A (en) * | 2012-12-25 | 2013-04-24 | 贵州省科晖制药厂 | Quality test method of phlegm eliminating and cough stopping granules for children |
-
2016
- 2016-12-17 CN CN201611171838.2A patent/CN106619686A/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103063792A (en) * | 2012-12-25 | 2013-04-24 | 贵州省科晖制药厂 | Quality test method of phlegm eliminating and cough stopping granules for children |
Non-Patent Citations (6)
| Title |
|---|
| 倪伟: "《内科学 第10版 新世纪第4版》", 31 July 2016, 中国中医药出版社 * |
| 北京中医学院: "《药剂学 （试用教材）》", 30 April 1975 * |
| 南京中医药大学: "《中药大辞典 第2版 下》", 30 June 2014, 上海科学技术出版 * |
| 孙文燕，张硕峰: "《图表解中医备考丛书 中药药理学》", 31 July 2013, 孙文燕，张硕峰 * |
| 张耕，马威，徐宏峰: "《常用中药毒性研究进展及应用》", 30 September 2013, 湖北科学技术出版 * |
| 艾铁民: "《中国药用植物志 第10卷》", 31 March 2014, 北京大学医学出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8394423B2 (en) | Compositions comprising apocynin, ginkgo and ginger and uses thereof | |
| CN111388582A (en) | Traditional Chinese medicine composition for treating novel coronavirus pneumonia and application of preparation thereof | |
| AU2018446089B2 (en) | Pharmaceutical use of anemoside B4 against acute gouty arthritis | |
| CN106619686A (en) | Western medicine for treating bronchiectasis | |
| CN104306793B (en) | A kind of Chinese medicine preparation for treating lobar pneumonia | |
| CN106668599A (en) | Drug for treating bronchiectasis | |
| CN103417571A (en) | Composition for treating chicken mycoplasma respiratory infection and preparing method thereof | |
| CN106491853A (en) | A kind of Chinese medicine and western medicine combination for treating bronchiectasiss and preparation method thereof | |
| CN106728145A (en) | It is a kind of to treat Chinese and western medicinal composition of acute diarrhea and preparation method thereof | |
| CN105726491A (en) | Polyhexamethylene guanidine medicine for treating stomach disease and preparation method and application thereof | |
| CN106511665A (en) | Pharmaceutical for treating allergic pneumonia | |
| CN106822133A (en) | A kind of Western medicine compound for treating acute diarrhea | |
| JP2009108044A (en) | Pharmaceutical composition comprising azelastines and antiphlogistic enzyme agent | |
| CN106668048A (en) | Western medicine for treating diffuse fibrosis of lung | |
| CN107198738A (en) | A kind of joint anti-inflammatory analgesic massage liquid and preparation method thereof | |
| CN106668600A (en) | Composite preparation for treating chronic glomerulitis | |
| CN103006986B (en) | Traditional Chinese medicine for treating children cough and preparation method of external use patch thereof | |
| CN106619680A (en) | Western medicine for treating chronic respiratory failure | |
| CN106727494A (en) | A kind of Western medicine for treating Eaton agent pneumonia | |
| CN106822239A (en) | It is a kind of to treat Chinese and western medicinal composition of the infection of the upper respiratory tract and preparation method thereof | |
| CN106692480A (en) | Western medicine for treating ventilation function failure | |
| CN106581032A (en) | Western medicine for treating hylactic pneumonia | |
| CN105380925A (en) | Ambroxol-salbutamol control released granule | |
| CN106727600A (en) | It is a kind of to treat Chinese and western medicinal composition of bronchial astehma and preparation method thereof | |
| CN105362226A (en) | Preparation method of ambroxol salbutamol aerosol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170510 |
|
| WW01 | Invention patent application withdrawn after publication |